The Q2 result was announced after market hours on Monday, 3 November 2014.

Meanwhile, the S&P BSE Sensex was up 137.41 points or 0.49% at 27,997.79.

On BSE, so far 2,321 shares were traded in the counter as against average daily volume of 2,907 shares in the past one quarter.

The stock hit a high of Rs 902.60 and a low of Rs 868 so far during the day. The stock had hit a 52-week low of Rs 725.85 on 4 February 2014. The stock had hit a 52-week high of Rs 1,285 on 4 March 2014.

The stock had underperformed the market over the past one month till 3 November 2014, advancing 0.52% compared with Sensex's 4.86% rise. The scrip had also underperformed the market in past one quarter, tumbling 17.78% as against Sensex's 9.34% rise.

The small-cap company has equity capital of Rs 5 crore. Face value per share is Rs 2.

AstraZeneca Pharma India's net sales declined 0.9% to Rs 114.55 crore in Q2 September 2014 over Q2 September 2013.

AstraZeneca Pharma India is one of the leading pharmaceutical companies, with a broad range of medicines designed to fight disease in important areas of healthcare. The company is involved in both manufacturing and marketing of medicines.